Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Consensus "Buy" rating: Five analysts rate Aktis Oncology a consensus Buy with an average 12‑month target of $32, and recent initiations/upgrades include JPMorgan (Overweight, $30), Bank of America (Buy, $34), TD Cowen (Buy) and HC Wainwright (Buy, $33) which cut loss estimates.
• Significant insider buying: Major shareholder Ansbert Gadicke bought 1,112,777 shares at $18 ($20.03M) and director Helen Susan Kim bought 835,000 shares at $18 ($15.03M); insiders acquired 6,117,776 shares this quarter (~$110.12M) and now own about 3.30% of the stock.
• Clinical and financial outlook: The FDA cleared INDs for AKY‑2519, providing a development catalyst, but the company remains loss‑making (consensus ≈ ($0.43) FY EPS) and the stock trades below its 50‑day moving average, highlighting execution and financing risks.

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $32.00.

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Aktis Oncology to a "hold" rating in a research note on Saturday, January 17th. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an "overweight" rating and a $30.00 target price for the company. TD Cowen started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a "buy" rating on the stock. Bank of America started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a "buy" rating and a $34.00 price target for the company. Finally, HC Wainwright lifted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a research report on Tuesday.

Insider Activity

In other news, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider directly owned 10,260,064 shares in the company, valued at approximately $184,681,152. The trade was a 12.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Helen Susan Kim acquired 835,000 shares of the company's stock in a transaction on Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the acquisition, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Stock Performance

Shares of NASDAQ:AKTS opened at $17.37 on Friday. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16. The firm has a fifty day moving average price of $19.03.

More Aktis Oncology News

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across 2026 and 2027 quarters and kept a "Buy" rating with a $33 price target — the analyst materially reduced expected losses for Q1–Q4 2026 (e.g., Q1: from ($0.64) to $0.36); Q2: ($0.71 to $0.38); Q3: ($0.77 to $0.46); Q4: ($0.83 to ($0.51)) and lifted FY2026 and FY2027 loss estimates FY2026: ($2.95 to ($1.72); FY2027: ($3.71) to ($2.35)). That optimism is likely driving buying interest. Aktis Oncology NASDAQ: AKTS Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Aktis announced FDA clearance of investigational new drug (IND) applications for AKY-2519 and provided business updates and full‑year 2025 financial results — IND clearances are a clear clinical development catalyst that can increase the stock’s upside if trials progress on schedule. Aktis Oncology Announces FDA Clearance of INDs for AKY-2519
• Neutral Sentiment: Market data and coverage references (e.g., Barron's stock page) provide third‑party visibility but add no immediate catalyst; useful for background research. Aktis Oncology Inc. — Barron's
• Negative Sentiment: Despite upgrades and IND clearance, consensus fundamentals remain loss-making (current full‑year consensus ≈ ($0.43) EPS) and the stock trades below its 50‑day moving average—ongoing development risk, cash burn and execution risk could pressure the share price if clinical or financing developments disappoint.

About Aktis Oncology

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.